Nanyang Technological University, Singapore
Position: Deputy Director of the Nanyang Institute of Technology in Health and Medicine, Head of the Translational Science Group at Nanyang Technological University, Singapore
Specialization: Biosensing, Hydrogel Livre Tissue Engineering, Drug Delivery
At the NANOCON´19 conference Nam-Joon Chon will present an invited lecture at the session C.
Personal Background and Education:
Originally from Seoul, South Korea, Dr. Cho is a graduate (BS Eng.) of the University of California, Berkeley (1996) and Stanford University (MS in 2003 and Ph.D. in 2006). He earned his doctorate in Chemical Engineering at Stanford under the guidance of Professor Curtis W. Frank. During his graduate studies, Dr. Cho first gained an interest in research at the interface of molecular virology and biomaterials. The principal goal of his thesis work was to develop lab-on-a-chip technologies for analysis of viral protein interactions with lipid membranes.
Nam-Joon Cho then continued his postdoctoral training in Professor Jeffrey S. Glenn's group in the Division of Gastroenterology and Hepatology at the Stanford University School of Medicine. He applied engineering technologies to combat the hepatitis C virus (HCV), which affects over 170 million people worldwide. His work has led to significant advances for treating HCV, including new drugs currently in preclinical or clinical trials. In addition, Dr. Cho has pioneered a novel approach to liver tissue engineering that has provided improved methods to study liver disease.
Research Interests and main results:
The research group of Dr. Nam-Joon Cho is focused on engineering approaches with strong emphasis on: 1) biosensing, 2) hydrogel tissue engineering, 3) biopharmaceuticals, and 4) drug delivery. The group develops model membrane sensing platforms to interrogate the mechanisms of virus life cycles, especially that of the Hepatitis C virus (HCV). They also leverage these engineering strategies to combat a wide range of viruses including dengue and influenza. And they characterize the molecular interactions of phospholipases involved in inflammatory response and the pathogeneses of many cancers. In the regenerative medicine the group is focused on liver tissue engineering.
Overall research initiative of the group seeks to engineer artificial membrane and tissue platforms to probe biological systems and to translate these findings into enhanced therapeutic and drug delivery options that more effectively target infectious diseases, inflammatory disorders, and cancer.
210 research papers and 3.421 citations, H-index: 32
Dr. Cho has been recognized by several prestigious international honors and awards from the American Liver Foundation, Beckman Foundation, and leading global universities and companies including Chalmers University of Technology and Roche Ltd.